LQDA
Liquidia Corp
NASDAQ · Healthcare · Biotechnology · US
$44.99
−1.60%Year over year
Reported trailing growth
- Revenue
- +2233.6%
- EBITDA
- +245.9%
- EBIT
- +222.0%
- EPS
- +192.8%
- Free cash flow
- +148.8%
- Operating cash flow
- +168.1%
Forward estimates
Based on analyst estimates
- Revenue
- +72.3%
- EBITDA
- -1.5%
- EPS
- -33.2%
Three-year CAGR
- Revenue
- +115.0%
- EBITDA
- +62.6%
- EBIT
- +57.6%
- Net income
- +47.1%
- EPS
- +51.8%
- Free cash flow
- +59.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026